Table 3.
Samples’ characteristics by trial arm of studies on efficacy of naftidrofuryl compared with placebo for treatment of intermittent claudication. Values are numbers (percentages) of patients unless specified otherwise
| Variables | Overall (n=1266) | Naftidrofuryl (n=640) | Placebo (n=626) |
|---|---|---|---|
| Mean (SD) age (years) | 62.41 (9.48) | 62.45 (9.39) | 62.36 (9.58) |
| Mean (SD) body mass index | 24.92 (3.26) | 24.93 (3.57) | 24.92 (2.91) |
| Mean (SD) systolic blood pressure (mm Hg) | 148.96 (20.92) | 148.63 (20.67) | 149.3 (21.18) |
| Mean (SD) ankle brachial index | 0.65 (0.17) | 0.64 (0.17) | 0.64 (0.17) |
| Mean (SD) duration of peripheral arterial disease (years) | 3.35 (3.41) | 3.42 (3.52) | 3.29 (3.3) |
| Geometric mean (95% CI) walking distance (m) | 140.44 (135.00 to 146.11) | 140.62 (133.07 to 148.61) | 140.26 (132.52 to 148.45) |
| Women | 222 (17.5) | 121 (18.9) | 101 (16.1) |
| Obesity | 592 (46.8) | 295 (46.1) | 297 (47.4) |
| Current smoker | 630 (49.8) | 331 (51.7) | 299 (47.8) |
| Hypertension | 710 (56.1) | 372 (58.1) | 338 (54) |
| Type 2 diabetes | 170 (13.4) | 96 (15) | 74 (11.8) |
| Hyperlipidaemia | 486 (38.4) | 242 (37.8) | 244 (39) |
| Sedentary | 541 (42.7) | 278 (43.4) | 262 (41.9) |
| Angina | 142 (11.2) | 82 (12.8) | 60 (9.6) |